Welcome to our dedicated page for 180 Life Sciences SEC filings (Ticker: ATNFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ATNFW SEC filings page aggregates regulatory documents related to the public warrants of 180 Life Sciences Corp. and the company’s broader corporate activities. 180 Life Sciences, described in its disclosures as a clinical-stage biotechnology company focused on inflammatory diseases, fibrosis and pain, files periodic and current reports that explain how its financings, governance decisions and strategic shifts affect both its common stock (ATNF) and warrants (ATNFW).
Recent Form 8-K filings detail significant capital markets transactions, including private placements of common stock and pre-funded warrants, the issuance of strategic advisor warrants, and a senior secured convertible note financing. These filings describe offering structures, warrant terms, conversion prices, registration rights agreements and related collateral arrangements, which are important for understanding dilution, potential share issuance and warrant overhang.
Other 8-Ks and proxy materials explain amendments to the company’s omnibus incentive plans, adoption of a 2025 option incentive plan, and an increase in authorized common shares. A series of filings in July and August 2025 describe the launch of a digital asset treasury strategy centered on acquiring Ether (ETH), the engagement of an asset manager, and the company’s ETH holdings, as well as the use of ETH and cash in connection with financings.
Filings dated August 2025 also document a name change from 180 Life Sciences Corp. to ETHZilla Corporation and the planned change of Nasdaq trading symbols from ATNF to ETHZ for common stock and from ATNFW to ETHZW for public warrants. These documents provide the authoritative record of the corporate transition and its impact on security identifiers.
On Stock Titan, users can access these SEC filings in one place, with AI-powered summaries that highlight key terms in 8-Ks, proxy statements and other disclosures. The platform is designed to help readers quickly identify material information about financings, warrant issuances, equity plans, governance changes and the evolution of the company’s capital structure that are relevant to the historical ATNFW warrants.
Stephen H. Shoemaker, a director of 180 Life Sciences Corp. (ticker shown as ATNF), reported a sale of 132,439 common shares and the receipt of a grant of 181,422 non-qualified stock options. The options carry an exercise price of $3.01 and were granted in consideration for services as a director; they vested immediately but are not exercisable until stockholder approval of the issuer's 2025 Second Supplemental Option Plan is received. If that approval is not obtained before August 8, 2026, the options will be cancelled. Following the reported transactions, the reporting person beneficially owns 181,422 option-based shares (direct). The filing discloses both an immediate disposal of existing common stock and a conditional, potentially dilutive option award tied to shareholder approval.
180 Life Sciences Corp. director Smith, Ryan Lewis reported transactions dated 08/08/2025. The filing shows a disposal of 167,181 common shares and a grant of 771,044 non-qualified stock options with an exercise price of $3.01 and an expiration shown as 08/08/2035. The options vested immediately but are not exercisable until stockholder approval of the 2025 Second Supplemental Option Plan; if approval is not received before 08/08/2026 the options will be cancelled. The filing states the options were issued in consideration for services as a director. The form is signed 08/11/2025.
180 Life Sciences Corp. reported that Director and Chief Executive Officer Jordan Blair received a grant of 771,044 non-qualified stock options on 08/08/2025 under the company’s 2025 Second Supplemental Option Plan with an exercise price of $3.01. The options vested immediately but are not exercisable until stockholder approval of the plan; if approval is not received by 08/08/2026 the options will be cancelled. The options expire on 08/08/2035 and were issued as consideration for services rendered.
The filing shows Mr. Blair’s indirect holdings include 327,576 shares through Blair Jordan Strategy and Finance Consulting Inc. and irrevocable voting proxies covering 43,166, 200,000 and 1,318,000 shares from three parties, where he has voting authority only and no dispositive control or pecuniary interest in those shares.
Reporting persons including FF Consumer Growth II, LP; FF Consumer Growth, LLC; and Peter Thiel disclosed beneficial ownership in 180 Life Sciences Corp. common stock. The filing shows FFCG II directly holds 8,935,990 shares (5.8%) and FFCG LLC directly holds 2,656,251 shares (1.7%). Collectively, Peter Thiel is reported to beneficially own 11,592,241 shares, or 7.5% of the class.
The percentages in the filing are calculated using 154,032,084 shares outstanding. The statement was submitted on Schedule 13G and the reporting persons disclaim status as a group and certify the securities were not acquired to change or influence control of the issuer.
180 Life Sciences entered into a Securities Purchase Agreement and closed a debt financing that issued senior secured convertible notes with an aggregate principal amount of $156,250,000 in exchange for cash equal to 96.0% of that principal, or $150,000,000. The notes bear 0.00% interest for the first six months, 4.00% for the following six months through maturity (three years), and carry an 18.0% default rate. The notes are secured by $44.5 million of Ether (ETH) and approximately $156.25 million in cash collateral.
The notes are convertible at an initial $3.445 per share conversion price, subject to a one-time downward-only reset after nine months, and conversion is capped so that conversions cannot cause the holder to exceed 19.99% ownership without stockholder approval. If converted in full at the stated conversion price, up to 45,355,588 shares could be issued. The company also issued 9,071,110 Subsequent Strategic Advisor Warrants at a $3.445 exercise price and adopted a 2025 supplemental option plan reserving 1,814,221 shares; option grants were approved for certain officers and advisors at a $3.01 exercise price. The filing also reports the appointment of McAndrew Rudisill as Executive Chairman and formation of an Investment Committee to oversee ETH and other digital assets.